Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide

Biotherapy

Volumn 11, Issue 4, 1998, Pages 223-228

  Li, Li ^a   Okino, Takashi ^a   Kan, Norimichi ^a   Yamasaki, Seiji ^a   Ichinose, You ^a   Sugie, Tomoharu ^a   Kanaoka, Shunji ^a   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Active specific immunization; Cyclophosphamide; rIL 1 ; Sonicated tumor supernatant

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 1BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; EFFECTOR CELL; HELPER CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SPLEEN CELL; SPLEEN WEIGHT; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-1; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; PLASMACYTOMA; RECOMBINANT PROTEINS; SPLEEN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032412113     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008054611739     Document Type: Article

References (13)

1. Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T Experimental study on the optimal treatment schedule for combination of BRM (Immunostimulators. Cultured killer cells or interleukin-2) and chemotherapy. Jpn J Cancer Chemother, 1990; 17: 1421-1427. (in Japanse)
2. Harada T, Kan N, Ichino.se Y, Moriguchi Y, Li L, Sugie T, Okino T, Imamura M The synergistic anti-tumor effect of recombinant interleukin-1 and low-dose of cyclophosphamide in tumor-bearing mice. J Surg Oncol, 1994; 56: 39-45.
3. Kan N. Okino T. Nakanisi M, Satoh K, Mise K. Yamasaki S, Teramura Y, Ohgaki K. Tobe T Therapeutic efficacy of sequential therapy with OK-432. cyelophosphamide. IL-2-eultured lymphocytes and in vivo IL-2 against advanced murinc plasmacytoma. Biotherapy. 1989; 1: 197-206.
4. Hanida T, Kan N, Okino T. Ichinosc Y. Moriguchi Y, Li L, Sugic T. Ohgaki K, Imamura M The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine model. Surg Today 1994; 24: 561-563
5. Moriguchi Y, Kan N, Okino T, Harada T. Yamasaki S, Ichinose Y, Li L. Sugie T. Imamura M A new model of active specific immunotherapy using Interleukin-l and sonicated tumor supernatant in murine tumor system. J Surg Oncol 1996. 62: 78-85.
6. Li L. Okino T, Sugie T, Yamasaki S, Ichinose Y, Kanaoka S, Kan N, Imamura M. Cyelophosphamide given after active specific immunization augments antitumor immunity by modulation of Thl commitment of CD4+T cells. J Surg Oncol, in press.
7. Harada T, Kan K, Okino T, Ichinose Y, Moriguchi Y. Li L, Sugie T. Ohgaki K, Imamura M Sequential immunotherapy using interleukin-1 followed by intcrleukin-2 of ascitic MOPC104E- bearing mice. Biotherapy 1994: 7: 91-99
8. Kan N, Ohgaki K, Inamoto T, Kodama H Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 1984; 18: 215-222
9. Winn H J: Immune mechanisms in homotransplantation II. Quantitative assay of the immunological activity of lymphoid cells stimulated by tumor homograft. J Immunol 1961; 86: 228-239
10. Hanna MG. Key ME: Immunotherapy of métastases enhances subsequent chemotherapy. Science 1982. 217: 367-369.
11. Lee KK. Goedgebuure PS, Linehan DC. Eberlein T J Immunoregulatory effects of CD4+ T helper subset in human melanoma. Surgery 1995, 117: 365-372.
12. Evans R, Duffy TM, Kamder SJ Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system. Eur J Immunol 1991, 21: 1815-1821.
13. Yamaki T, Ueda T, Shijuba N Functional analysis of mononuclear cells infiltrating into tumors. Ill, soluble factors involved in the regulation of T lymphocytes infiltration into tumors. J Immunol 1988, 140:4389-4396